NCT04356963

Brief Summary

Severe and refractory pain after acute injury is a known-risk factor for chronic opioid use disorder. In this study, the investigators will use Virtual Reality (VR) immersion as a non-pharmacological adjunct to treat pain associated with acute traumatic injuries, including traumatic brain injury. The investigators hypothesize that VR therapy will decrease pain and reduce opioid use in patients with acute traumatic injuries, including TBI.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2020

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 19, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 22, 2020

Completed
5 months until next milestone

Study Start

First participant enrolled

September 5, 2020

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 7, 2022

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2022

Completed
12 months until next milestone

Results Posted

Study results publicly available

April 24, 2023

Completed
Last Updated

April 24, 2023

Status Verified

April 1, 2023

Enrollment Period

1.3 years

First QC Date

April 19, 2020

Results QC Date

January 27, 2023

Last Update Submit

April 1, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Pain Score

    Pre- vs. Post-Intervention Ratings on Numeric Pain Rating Scale. Numeric Pain Rating scale range is from 0 (no pain) -10 (severe pain)

    Pre- and Post-Intervention (approximately 30 minutes)

Secondary Outcomes (1)

  • Opioid Administration

    4 hours post-intervention vs. 4 hours pre-intervention

Other Outcomes (5)

  • Change in Nausea

    Pre- and Post-Intervention (approximately 30 minutes)

  • Change in Anxiety

    Pre- and Post-Intervention (approximately 30 minutes)

  • Change Heart Rate Variability

    Mean NN from last 15 minutes of each intervention compared to mean NN from 15 minutes immediately prior to intervention

  • +2 more other outcomes

Study Arms (1)

All patients

EXPERIMENTAL

All patients were intended to engage in three different 20-30 min sessions run by research coordinators and spaced a minimum of 4 hours apart to allow for washout of effects, including 1) a commercially available, immersive VR environment, theBlu (WEVR, Inc, Venice, California, USA) delivered via Oculus Rift (Oculus VR, Irvine, California, USA) headset (VR Blu), 2) a non-immersive two-dimensional mimic delivered via a tablet computer (Tablet Blu), and 3) a VR control session delivered via a content-less Oculus Rift headset (VR Blank). The three sessions were run by research coordinators and spaced a minimum of 4 hours apart. The intervention order was counterbalanced using a randomized sequence generator.

Behavioral: Virtual Reality Session (VR Blu)Behavioral: Tablet-based Session (Tablet Blu)Behavioral: Use of Virtual Reality Head Mounted Display without Content (VR Blank)

Interventions

20-30 minute session of virtual reality immersive content.

All patients

20-30 minute session of tablet-based content that mimics the content from virtual reality sessions.

All patients

20-30 minutes session using head mounted display to reduce light and sound.

All patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of Traumatic Injury (including but not limited to traumatic brain injury)
  • Age greater than or equal to 18 years-old
  • Endorsing at least moderate pain as defined by documentation of at least one numeric rating pain scale score of 3 or more in the last 24 hours.
  • Glasgow Coma Scale of 15
  • Expected to stay in the hospital for at least 12 hours after enrollment

You may not qualify if:

  • Seizure prior to enrollment
  • Pregnancy
  • non-English speaking
  • Known intolerance of Virtual Reality
  • Patient unable to consent for themselves

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

R Adams Cowley Shock Trauma Center

Baltimore, Maryland, 21201, United States

Location

University of Maryland Medical Center

Baltimore, Maryland, 21201, United States

Location

Related Publications (2)

  • Morris NA, Wang Y, Felix RB, Rao A, Arnold S, Khalid M, Armahizer MJ, Murthi SB, Colloca L. Adjunctive virtual reality pain relief after traumatic injury: a proof-of-concept within-person randomized trial. Pain. 2023 Sep 1;164(9):2122-2129. doi: 10.1097/j.pain.0000000000002914. Epub 2023 Apr 19.

  • Felix RB, Rao A, Khalid M, Wang Y, Colloca L, Murthi SB, Morris NA. Adjunctive virtual reality pain relief following traumatic injury: protocol for a randomised within-subjects clinical trial. BMJ Open. 2021 Nov 30;11(11):e056030. doi: 10.1136/bmjopen-2021-056030.

MeSH Terms

Conditions

Brain Injuries, TraumaticPost-Traumatic HeadacheWounds and InjuriesAcute Pain

Condition Hierarchy (Ancestors)

Brain InjuriesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesCraniocerebral TraumaTrauma, Nervous SystemHeadache Disorders, SecondaryHeadache DisordersPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Limitations and Caveats

Very few patients with TBI met inclusion criteria. The intervals between conditions were quite short to improve feasibility of study completion based on brief anticipated length of stay. This limited our ability to evaluate effects on opioid use and duration of VR intervention effect. The sample size limited our ability to account for multiple comparisons.

Results Point of Contact

Title
Dr. Nicholas Morris
Organization
University of Maryland School of Medicine

Study Officials

  • Nicholas A Morris, M.D.

    University of Maryland, Baltimore

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Masking Details
Interventions will take place in patient rooms with curtain pulled and sign to mask active intervention vs. control intervention from care providers.
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Within-Subjects Design. All participants (single group, 1 arm) intended to complete all three sessions (interventions) in randomized order. At least 4 hours were required to pass between each session to allow for washout.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Neurology

Study Record Dates

First Submitted

April 19, 2020

First Posted

April 22, 2020

Study Start

September 5, 2020

Primary Completion

January 7, 2022

Study Completion

April 30, 2022

Last Updated

April 24, 2023

Results First Posted

April 24, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will not share

Locations